Factors leading to tracheobronchial self-expandable metallic stent fracture  by Chung, Fu-Tsai et al.
GENERALTHORACIC SURGERYFactors leading to tracheobronchial self-expandable metallic stent
fracture
Fu-Tsai Chung, MD,* Shu-Min Lin, MD,* Hao-Cheng Chen, MD, Chun-Liang Chou, MD, Chih-Teng Yu, MD, Chien-
Ying Liu, MD, Chun-Hua Wang, MD, Horng-Chyuan Lin, MD, Chien-Da Huang, MD, and Han-Pin Kuo, MD, PhD
Objective: This retrospective study was to determine factors that contribute to self-expandable metallic stent
fracture in patients with tracheobronchial disease.
Methods: From 2001 to 2006, 139 patients (age, 62.1 15.4 years; range, 23–87 years) with benign (n¼ 62) and
malignant (n ¼ 77) tracheobronchial disease received 192 Ultraflex (Boston Scientific, Natick, Mass) self-
expandable metallic stents (98 in patients with benign disease and 94 in patients with malignant disease).
Results: Seventeen fractured self-expandable metallic stents were found; the incidence was 12.2% (17/139 pa-
tients) among patients with tracheobronchial disease. Tortuous airway (odds ratio, 4.06; 95% confidence interval,
1.04–18.34; P ¼ .04) independently predicted self-expandable metallic stent fracture. Most self-expandable me-
tallic stent fractures (64.7%, 11/17) were detected 500 to 1000 days after self-expandable metallic stent implan-
tation. Clinical presentations for patients with fractured self-expandable metallic stents included dyspnea
exacerbation (70.6%, 12/17) and cough (23.5%, 4/17).
Conclusions: Self-expandable metallic stent fracture is not uncommon in patients with tracheobronchial disease.
Tortuous airway is an independent predictor for it. Although management of the fractured self-expandable metallic
stent in our study was feasible and safe, self-expandable metallic stents should be restricted to a more select population.G
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SEndoscopic airway stent implementation for airway stenosis
has been an increasingly popular treatment over the last de-
cade. Silicone stents are widely used in the maintenance of
airway patency because they are easily removed and reposi-
tioned.1,2 However, their complications include migration,
granulation tissue formation, and airway obstruction. Metal-
lic stent management of tracheobronchial obstruction was
introduced 10 years ago.3 Since then, self-expandable metal-
lic stents (SEMSs) have become widely used for manage-
ment of benign and malignant airway disease. They can be
successfully implanted with a flexible bronchoscope during
conscious sedation and local anesthesia.4-6
Although the US Food and Drug Administration an-
nounced a warning for the use of SEMSs in benign con-
ditions, many patients received this therapeutic modality
before the warning. In addition, among patients who refused
surgical intervention or were not suitable for surgical inter-
vention because of medical comorbidity or poor pulmonary
function, metallic stents were reported to be safe and effec-
tive in patients with benign and malignant airways obstruc-
tion.7,8 Unlike silicone stents, SEMSs have decreased
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doi:10.1016/j.jtcvs.2008.05.0391328 The Journal of Thoracic and Cardiovascularmigration rates, greater cross-sectional airway diameters (be-
cause of thinner wall construction), better conformation with
irregular airways, epithelialization within the stent that main-
tains mucociliary clearance, and easier placement.4,9
Although SEMSs adequately manage the narrow airway
lumen caused by tracheobronchial diseases, complications in-
clude stent fracture, migration, granulation tissue formation,
impaired mucociliary clearance, recurrent stent obstruction
by the lumen, and increased bacterial infection.3,10,11 There-
fore because of these complications, the US Food and Drug
Administration warned that SEMS implantation should be
considered only if the patients are not eligible for surgical in-
tervention, rigid bronchoscopy, or silicone stent implantation.
However, previous studies reported that SEMSs offer benefits
in long-term treatment for benign central tracheal stenosis in
a certain group of patients,12,13 but the characteristics of the
patients who would benefit from SEMS implantation were
not well defined.
Among the potential complications of SEMSs, fracture is
of major concern because it can cause potential obstruction
and wall perforation.14 Proposed causes of such fractures in-
clude repetitive coughing, esophageal compression during
swallowing,10 metal fatigue,4 granulation, and shearing
forces.15 However, contributory factors to fracture have
not been well documented.10,15 This study explores these
factors in patients with tracheobronchial disease.
MATERIALS AND METHODS
Patients
From August 2001 to September 2006, 139 patients (age 62.1  15.4
years) underwent 192 endoscopic airway stent placements at Chang Gung
Memorial Hospital, a university-affiliated hospital in Northern Taiwan.Surgery c November 2008
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SAbbreviations and Acronyms
CI ¼ confidence interval
IQR ¼ interquartile range
IRB ¼ institutional review board
SEMS ¼ self-expandable metallic stent
Ninety-eight stents were used in 62 patients with benign tracheobronchial
disease, whereas 94 stents were used in 77 patients with malignancy. Silicon
or other metallic stents were used by thoracic surgeons in our institution.
However, most of them require rigid bronchoscopic intervention. Thoracic
surgeons were routinely consulted for feasibility of surgical intervention for
all the benign diseases before SEMS implantation. Of 62 patients with be-
nign disease, 37 patients with poor pulmonary function and 19 patients with
severe comorbid conditions were precluded from surgical intervention. The
other 6 patients refused surgical intervention. Informed consent was ob-
tained from all patients or their surrogates before the procedure of broncho-
scopic SEMS implantation and follow-up. Methodology and patient
confidentiality were approved by our institutional review board (IRB).
The IRB was also asked to review the design of the project in December
2006 and approved this retrospective study in March 2007. The IRB con-
firmed that this study constituted an audit, which did not require patient con-
sent to this retrospective study.
Stent Implantation
SEMSs were implanted by means of flexible bronchoscopy during con-
scious sedation and local anesthesia. The choice of stent length and type
(with or without cover) was determined by means of previous endoscopic
examination and chest computed tomographic scanning. SEMSs were im-
planted at the choke point, as determined by using flow–volume curve, en-
dobronchial ultrasonography, bronchoscopy, or 3-dimensional computed
tomography before and after stenting.16 Ultraflex (Boston Scientific, Natick,
Mass), a tightly weaved SEMS composed entirely of a single strand of
nickel–titanium alloy, was the stent of choice for this study.
Assessment of Stent Condition
After implantation of the stent, a second bronchoscopic study was per-
formed in 48 hours. The presence of incomplete stent expansion and incom-
plete stent lumen expansion was recorded and evaluated in the follow-up
bronchoscopic studies. In addition, each patient underwent bronchoscopic
examination 1 week after implantation and then every 3 to 6 months there-
after to evaluate stent position and degradation, granulation tissue forma-
tion, and airway alignment. If dyspnea, severe coughing, increased mucus
production, or other fracture symptoms occurred, additional bronchoscopic
analysis was performed.
Definition of Airway and SEMS Conditions
SEMS fracture was defined as the physical breaking of the stent (Figure 1).
A tortuous airway was defined as a failure to visualize either the main carina
from the trachea or the second carina from either the main bronchus during
bronchoscopy (Figure 2) or torsion of the airways on radiographic imaging
study (Figure 3). The airway disease was defined as patients with asthma or
chronic obstructive pulmonary disease. Incomplete stent lumen expansion
was defined because the lumen does not complete expansion after stent im-
plantation for more than 72 hours. Narrow stent opening was defined because
the shape of the stent was not round or ovoid after implantation.
Treatment for SEMS Fracture
The treatment strategies for stent fracture include stent removal,17 an-
other stent implantation, or observation because of no symptoms. PatientsThe Journal of Thoracic and Cawho underwent SEMS implantation or removal were consciously sedated
with midazolam during flexible bronchoscopy. Electrocautery and forceps
were applied alternatively to remove the fractured stent piece by piece
because SEMSs were usually tightly embedded into the epithelium of the
airway mucosa. SEMS removal usually costs several days’ hospitalization
because it is difficult to completely remove a stent at once. Although we
might spend hours removing the stent each time, neither mortality nor se-
vere morbidity occurred. The whole hospitalization course for each stent re-
moval was usually less than 1 week. The choice of treatment was judged
individually by bronchoscopists according to the patients’ clinical
FIGURE 1. A patient with self-expandable metallic stent fracture ex-
pressed as the physical breaking of the stent.
FIGURE 2. Tortuous airway expressed as failure to visualize either of the
main carina from the trachea during bronchoscopic analysis.rdiovascular Surgery c Volume 136, Number 5 1329
General Thoracic Surgery Chung et al
G
T
Smanifestations, imaging study results, and physical status. The numbers of
bronchoscopic interventions for fractured stents were listed.
Statistical Analysis
Analysis of variance and unpaired t tests were used to compare stent im-
plant duration and SEMS fracture detection with different variables, such as
stent location, stent type, and fracture site. Data are expressed as medians
and interquartile ranges (IQRs). Univariate analysis with the Fisher’s test
was primarily used for variable selection (P< .05). Significant variables,
such as underlying benign or malignant diseases, tortuous airway, covered
stent, stent implantation for longer than 1 year, and postoperative airway
condition, including granulation tissue formation, incomplete stent lumen
expansion, narrowing of the stent opening, and poor airway alignment (after
stent implantation), were entered into a forward logistic regression analysis
to determine the net effect of each predictor while controlling the net effects
of others. Odds ratios and 95% confidence intervals (CIs) were adopted to
assess significant independent contributions. Time to SEMS fracture was
defined as the period between the date of implantation and fracture detec-
tion. Kaplan–Meier analysis was used to determine the SEMS fracture
rate curve. Fractured curves between patients, with and without pre-existing
tortuous airways, were compared by using the log-rank test. All analysis was
performed with SPSS software, version 10.0 (SPSS, Inc, Chicago, Ill).
RESULTS
Baselines
From 2001 to 2006, 139 patients (age, 62.1  15.4 years;
range, 23–87 years) with benign (n ¼ 62) and malignant
(n ¼ 77) tracheobronchial disease received 192 Ultraflex
SEMSs (98 stents in patients with benign disease and 94
stents in patients with malignant disease). The indication
of SEMS implantation is presented in Table 1.
FIGURE 3. Tortuous airway on chest roentgenogram in a patient with self-
expandable metallic stent implantation.1330 The Journal of Thoracic and Cardiovascular SThe overall SEMS fracture incidence was 12.2% (17/139
patients). However, all fractures occurred only in patients
with benign lesions, with an incidence of 27.4% (17/62 pa-
tients). Treatment for stent fracture and total numbers of
bronchoscopic intervention for the patients with stent frac-
tures is shown in Table 2.
In total, of 62 patients with benign airway disease under-
going SEMS implantation, 39 (62.9%) patients were still
being followed up at the outpatient department, 12
(19.4%) patients were dead, and 11 (17.7%) patients were
lost to follow-up. The median duration of all SEMSs in pa-
tients with benign condition was 617 days (n ¼ 62; IQR,
224.5–1123 days), the median duration in patients still fol-
lowed up was 671 days (n ¼ 39; IQR, 309–1282 days),
the median duration in deceased patients was 644 days (n
¼ 12; IQR, 175.5–900.5 days), and the median duration in
patients lost to follow-up was 199 days (n ¼ 11; IQR, 65–
279 days).
In total, of 77 patients with malignancy undergoing
SEMS implantation, 3 (3.9%) patients were still followed
up at the outpatient department, 67 (87.0%) patients were
dead, and 7 (9.1%) patients were lost to follow-up. The me-
dian duration of all SEMSs in patients with malignancy was
61 days (n¼ 77; IQR, 19–106 days), the median duration in
patients still followed up was 315 days (n ¼ 3; range, 238–
474 days), the median duration in deceased patients was 50
days (n¼ 67; IQR, 17–97 days), and the median duration in
patients lost to follow-up was 109 days (n¼ 7; IQR, 34–197
days).
TABLE 1. Indication for self-expandable metallic stent implantation
No. of
patients
No. of
SEMSs
Malignancy
Lung cancer causing airway stricture 44 54
Esophageal cancer
Airway invasion with luminal stricture 3 3
TE fistula 24 31
Mediastinal tumor with airway compression 4 4
Other malignancy causing airway stricture 2 2
Subtotal 77 94
Benign
Malacia 26 56
Posttuberculosis airway stricture 8 8
Postintubation airway stricture 6 6
Granuloma causing previous SEMS restenosis 8 12
Previous SEMS fracture 5 5
Airway corrosive injury with stricture 2 3
Mediastinitis causing airway stricture 2 2
Previous SEMS fatigue 2 3
Goiter external compression 3 3
Subtotal 62 98
Total 139 192
TE, Tracheoesophageal; SEMS, self-expandable metallic stent.urgery c November 2008
Chung et al General Thoracic SurgeryTABLE 2. Self-expandable metallic stent implantation sites, properties, indication, and times to fracture
Stent
no. Location
Indication
of SEMS
implantation
With
cover
Time to
fracture (d)
Size, mm
(diameter
3 length)
Symptom
when
fracture
detected
Fracture
site of stent
Treatment for
stent fracture
No. of
bronchoscopies
1 Trachea Posttuberculosis
stenosis
þ 681 18 3 80 Dyspnea Proximal Removal and
restenting
7
2 Trachea Malacia  1170 18 3 60 Dyspnea Intraluminal Removal 8
3 Trachea Postintubation
stenosis
 276 20 3 60 Dyspnea Proximal Removal and
restenting
6
4 Trachea Malacia  617 20 3 80 Dyspnea Distal Removal 6
5 LL Malacia  733 10 3 20 Cough Proximal Removal 6
6 LM Malacia  686 14 3 40 Cough Intraluminal Removal 5
7 RL Malacia  709 12 3 20 None Proximal None 5
8 LM Posttuberculosis
stenosis
 522 14 3 40 Dyspnea Distal Removal and
restenting
8
9 Trachea Postintubation
stenosis
þ 99 20 3 40 Dyspnea Intraluminal Removal 5
10 RIB Malacia  856 14 3 40 Dyspnea Proximal Removal and
restenting
9
11 Trachea Malacia  7 20 3 60 Dyspnea Proximal Removal 3
12 Trachea Malacia  562 20 3 60 Cough Distal Removal 5
13 Trachea Posttuberculosis
stenosis
 905 18 3 60 Dyspnea Distal Removal 8
14 Trachea Posttuberculosis
stenosis
þ 772 20 3 40 Dyspnea Intraluminal Removal 8
15 Trachea Stent restenosis after
tissue granulation
 211 20 3 60 Dyspnea Distal Removal and
restenting
5
16 Trachea Postintubation stenosis  750 20 3 60 Cough Intraluminal Removal 6
17 Trachea Postintubation Stenosis þ 1266 20 3 80 Dyspnea Intraluminal Removal 8
SEMS, Self-expandable metallic stent;þ, with cover;, without cover LL, left lower bronchus; LM, left main bronchus; RL, right lower bronchus; RIB, right intermediate bronchus.G
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SUnivariate and Multivariate Analysis of SEMS
Fracture Factors
SEMS properties (length and size, presence of cover, and
implantation site), follow-up duration after SEMS implanta-
tion, structural factors (underlying benign or malignant dis-
eases, airway wall dynamic collapse, and tortuous airway),
postoperative airway conditions (poor airway alignment,
granulation tissue formation, narrow stent opening, and in-
complete stent lumen expansion), and other new postopera-
tive symptoms were included in the univariate SEMS
fracture analysis (Table 3). The dominant symptoms of stent
fracture include exacerbation of dyspnea (70.6%, 12/17) or
cough 23.5%, 4/17). One symptom-free fracture was found
during routine bronchoscopy.
For multivariate analysis, only underlying tortuous air-
way (odds ratio, 4.33; 95% CI, 1.09–18.3; P ¼ .04) acted
as an independent predictor of stent fracture (Table 4). Post-
operative granulation tissue formation (n ¼ 26, 36.6%; P<
.01), incomplete stent lumen expansion (n ¼ 27, 38%; P<
.01), narrow stent opening, (n ¼ 23, 32.4%; P< .01), and
poor airway alignment (n ¼ 35, 49.3%; P< .01) were all
more prevalent in patients with tortuous airways (n ¼ 71)
than in those without (n ¼ 121; 14.9%, 12.4%, 7.4%,The Journal of Thoracic and Cand 5.8%, respectively; Table 5). Cover stent, underlying
benign disease, duration of more than 1 year after stent im-
plantation, and presence of new postoperative symptoms,
such as dyspnea exacerbation, were not significantly differ-
ent between these groups (Table 5).
Time to SEMS Fracture in Patients With
Tracheobronchial Disease
Overall SEMS fracture incidence in this group varied with
time. The fracture rate was 2.1% (4/192) in the first year,
9.4% (6/64) in the second year, 13.9% (5/36) in the third
year, 11.1% (2/18) in the fourth year, and nil (0/11) in the
fifth year (Figure 4). Most fractures (64.7%, 11/17) were de-
tected 500 to 1000 days after implantation (Table 2). The in-
cidence increased rapidly after the second year for patients
with tortuous airways (Figures 5 and 6). Time to fracture de-
tection was not affected by stent location (trachea versus
bronchus: median, 649 days [IQR, 243.5–838.5 days; n ¼
12] vs 709 days [IQR, 604–794.5 days; n ¼ 5]; P ¼ .63),
type (covered vs uncovered: median, 726.5 days [IQR,
390–1019 days; n ¼ 4] vs 686 days [IQR, 399–803 days;
n¼ 13]; P¼ .664), or fracture site (proximal, distal, and intra-
luminal: median, 695 days [IQR, 141.5–794.5 days; n ¼ 6],ardiovascular Surgery c Volume 136, Number 5 1331
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STABLE 3. Univariate analysis of factors associated with self-expandable metallic stent fracture in patients with tracheobronchial disease (n¼ 192)
Factors Fracture incidence (%) Odds ratio 95% CI P value
SEMS implantation site
Trachea (n ¼ 116) 12 (10.3) 1.64 0.55–4.85 .37
Bronchi (n ¼ 76) 5 (6.6)
SEMS characteristics
Length of SEMS in trachea (n ¼ 116)
>6 cm (n ¼ 40) 3 (7.5) 1.66 0.42–6.50 .47
<6 cm (n ¼ 76) 9 (11.8)
Length of SEMS in bronchi (n ¼ 76)
>4 cm (n ¼ 66) 3 (4.4) 5.25 0.76–36.35 .07
<4 cm (n ¼ 10) 2 (20.0)
Size of SEMS in trachea (n ¼ 116)
>18 mm (n ¼ 62) 9 (14.5) 2.89 0.74–11.27 .11
<18 mm (n ¼ 54) 3 (5.6)
Size of SEMS in bronchi (n ¼ 76)
>14 mm (n ¼ 61) 3 (4.9) 2.97 0.45–19.65 .24
<14 mm (n ¼ 15) 2 (13.3)
Covered (n ¼ 120) 4 (3.3) 6.39 2.0–20.46 .0005
Uncovered (n ¼ 72) 13 (18.1)
Follow-up duration after SEMS implantation
1 y (n ¼ 62) 13 (21.0) 8.36 2.60–26.89 <.0001
<1 y (n ¼ 130) 4 (3.1)
Underlying diseases
Benign disease (n ¼ 98) 17 (17.3) 40.6 2.40–685.9 <.0001
Malignant disease (n ¼ 94) 0 (0)
Airway condition before SEMS implantation
Airway wall
Dynamic collapse (n ¼ 73) 8 (11.0) 1.50 0.55–4.09 .42
Fixed airway lesion (n ¼ 119) 9 (7.6)
Airway lumen
Tortuous airway (n ¼ 71) 12 (16.9) 4.72 1.59–14.03 .003
Nontortuous airway (n ¼ 121) 5 (4.1)
Airway condition after SEMS implantation
Poor airway alignment (n ¼ 42) 7 (16.7) 2.80 0.99–7.88 .04
Narrow stent opening (n ¼ 32) 8 (25.0) 5.59 1.97–15.91 .0004
Granulation tissue formation (n ¼ 44) 11 (25.0) 7.89 2.72–22.88 <.0001
Incomplete stent lumen expansion (n ¼ 42) 7 (16.7) 2.80 0.99–7.88 .04
New symptoms after SEMS implantation
Exacerbated postoperative dyspnea (n ¼ 86) 12 (14.0) 3.28 1.11–9.70 .03
Exacerbated postoperative coughing (n ¼ 65) 4 (6.2) 1.74 0.54–5.57 .35
CI, Confidence interval; SEMS, self-expandable metallic stent.562 days [IQR, 366.5–761 days, n ¼ 5], and 761 days [IQR,
392.5–1218 days, n ¼ 6]; P ¼ .414; Table 6). According to
log-rank test analysis (Figure 6), fracture incidence was
higher in patients with tortuous airways (62.6% vs 18.6%;
hazard ratio, 5.59; 95% CI, 2.06–14.82; P ¼ .0007).
DISCUSSION
Despite similar numbers of SEMSs implanted in patients
with malignancy, no stent fracture was detected in this
group, and this is likely because of the short survival time
of these patients, which precludes development of stent frac-
tures. Patients with malignancy-induced central airway ob-
struction only survived a median of 61 days (n ¼ 77; IQR,1332 The Journal of Thoracic and Cardiovascular Su19–106 days) after stent implantation. The median time to
stent fracture is 686 days (IQR, 399–814 days). In univariate
analysis duration of stent implantation of more than 1 year
(odds ratio, 8.36; P<.0001) contributes to stent fracture, al-
though the net effect disappears in multivariate analysis. Un-
derlying benign disease (odds ratio, 40.6; P< .0001) also
contributes to stent fracture in univariate analysis. It was
not able to analyze in multivariate analysis for all fractured
SEMS only found in patients with benign disease. A short
lifespan in patients with malignancy might not be long
enough for the development of stent fracture. These results
demonstrate that tracheobronchial stent fracture is not
uncommon in benign airway disease, and therefore otherrgery c November 2008
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Salternative therapeutic strategies should be evaluated before
SEMS implantation in patients with benign disease.
Although many possible causes of stent fracture have
been proposed, such as repetitive coughing, compression
from the esophagus during swallowing,10 metal fatigue,4
granulation, and shearing force,15 the mechanism for stent
fracture is still undetermined. This study demonstrates that
stent length and size, along with sites of implantation or frac-
ture, are not related to fracture. Structural factors (tortuous
airway and underlying benign disease), covered stent, post-
operative airway conditions (poor alignment, incomplete
stent lumen expansion, granulation tissue formation, and
narrow stent opening), duration of stent implantation of
more than 1 year, and new postoperative symptoms (dysp-
nea) are related to stent fracture. However, underlying tortu-
ous airway has proved to be the only independent predictor
for stent fracture. Logistic regression analysis revealed a 5-
fold increase in fracture risk for patients with tortuous air-
ways when compared with those without airway tortuosity.
The patients with tortuous airways also had a higher inci-
dence of granulation tissue formation, incomplete stent
TABLE 4. Multivariate analysis of factors associated with self-
expandable metallic stent fracture in patients with tracheobronchial
disease (n ¼ 192)
Factors Odds ratio 95% CI P value
Cover stent 0.06 0.18–3.79 .80
More than 1 y after stent implantation 1.18 0.51–10.52 .28
Underlying benign disease None None None
Underlying tortuous airway 4.06 1.04–18.34 .04
Poor postoperative airway alignment 0.08 0.15–4.20 .78
Narrow stent opening 0.56 0.28–17.47 .46
Granulation tissue formation 1.36 0.52-12.98 0.24
Incomplete stent lumen expansion 0.04 0.13–12.18 .84
Exacerbated postoperative dyspnea 1.11 0.56–7.09 .29
CI, Confidence interval.
TABLE 5. Postoperative airway conditions in patients with or without
tortuous airways
Contributing factors
Tortuous
airway
(n ¼ 71),
n (%)
Nontortuous
airway
(n ¼ 121),
n (%)
P
value*
Cover stent 42 (59.2) 78 (64.5) .46
More than 1 y after stent
implantation
24 (33.8) 38 (31.4) .73
Underlying benign disease 32 (45.1) 66 (54.5) .2
Poor airway alignment 35 (49.3) 7 (5.8) <.0001
Narrow stent opening 23 (32.4) 9 (7.4) <.0001
Granulation tissue formation 26 (36.6) 18 (14.9) .0005
Incomplete stent lumen
expansion
27 (38.0) 15 (12.4) <.0001
Newly developed dyspnea 30 (42.3) 56 (46.3) .59
*Fisher’s exact test.The Journal of Thoracic and Calumen expansion, poor airway alignment, and narrow stent
opening when compared with those without airway tortuos-
ity. Therefore SEMS implantation should be avoided in pa-
tients with benign central airway lesions and tortuous
airways.
The results suggest that stents implanted in tortuous air-
ways cannot maintain their ideal architecture and alignment.
Increased shearing forces on these stents, with subsequent
granulation tissue formation, might lead to fracture. Postop-
erative granulation tissue formation, stent expansion failure,
poor airway alignment, and narrow airway lumen all might
stem from a tortuous airway; they might not be independent
causes of stent fracture.
Notwithstanding the low case number in the fifth year,
overall SEMS fracture incidence increased with time. There
was no significant change in the incidence of SEMS fracture
with time in patients with nontortuous airways. Incidence in-
creased abruptly after 2 years in patients with tortuous
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FIGURE 4. Yearly overall self-expandable metallic stent (SEMS) fracture
incidence in patients with tracheobronchial disease.
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FIGURE 5. Yearly self-expandable metallic stent (SEMS) fracture inci-
dence in patients with or without tortuous airways.rdiovascular Surgery c Volume 136, Number 5 1333
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Sairways. No stent properties significantly affected the time to
fracture. Most SEMS fractures were detected after dyspnea
or cough exacerbation; however, there was 1 patient with
SEMS fracture who was totally asymptomatic. Therefore
regular bronchoscopic examination is mandatory after
SEMS implantation, particularly for patients with tortuous
airways after the first year.
Nevertheless, the high incidence of stent fracture in pa-
tients with benign airway diseases after a short-term fol-
low-up precludes SEMS implantation from replacing
surgical correction as a therapeutic intervention in patients
suitable for an operation. Surgical treatment in patients
with such benign airway diseases should be the first choice,
unless patients were unsuitable for surgical intervention be-
cause of poor lung function, comorbidities, or surgical re-
fusal. Still, the balance between clinical benefit and a risk
of stent fracture should be cautiously considered for SEMS
implantation in these patients. In patients with tortuous air-
ways, narrow stent opening, granulations, incomplete stent
expansion, benign airway diseases, covered stent implanta-
tion, or duration of stent implantation of more than 1 year,
regular radiologic or bronchoscopic examination and close
monitoring of exacerbation or new development of dyspnea
or coughing after SEMS implantation is mandatory.
Surgical treatment in patients with such benign airway
diseases should be the first choice. If patients were unsuit-
able for surgical intervention because of poor lung function,
comorbidities, or surgical refusal, SEMS implantation
during medical bronchoscopy would be tried if no other
treatment were available. However, these patients must be
closely monitored for development of new symptoms,
and radiologic or bronchoscopic examination should be
arranged.
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FIGURE 6. Logistic regression analysis of cumulative self-expandable
metallic stent (SEMS) fracture incidence in patients with or without tortuous
airways (62.6% vs 18.6%; hazard ratio, 5.59; 95% confidence interval,
2.06–14.82; P ¼ .0007).1334 The Journal of Thoracic and Cardiovascular SuThe treatment for SEMS fracture is feasible in our study.
There were higher total numbers of bronchoscopic interven-
tions after SEMS implantation in patients with stent frac-
tures than in those without (mean  SD, 6.35  1.62 vs
3.03  2.5; P< .0001, not shown on tables). No mortality
or sever morbidity developed during and after broncho-
scopic intervention for a fractured stent in our study.
In summary, SEMS fracture is not uncommon in patients
with benign tracheobronchial disease, and a tortuous airway
is an independent predictor for it. SEMS fracture incidence
increases dramatically 2 years after implantation. A prospec-
tive study with regular radiologic or bronchoscopic exami-
nation is warranted to evaluate the true incidence of stent
fracture, even in the absence of symptoms. In conclusion,
given the high rate of stent failure among patients with be-
nign disease, metal stents should be restricted to a highly se-
lected population rather than all patients with benign disease
to specifically avoid situations in which long-term use of the
stent is anticipated.
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